Browse studies

Find your next paid study

27,295 recruiting studies available now

TAD1 Risk Assessment for Cardiac Amyloidosis With Evuzamitide (TRACE)

The goal of this study is to learn whether PET-CT imaging using evuzamitide can help diagnose transthyretin cardiac amyloidosis (ATTR-CA) in patients whose sta…

Amyloidogenic Transthyretin (ATTR) AmyloidosisCardiac Amyloidosis

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Lorena SaelicesNCT07538518

Phase 1

A Phase 1, Single-Dose, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Aleniglipron Pharmacokinetics

The purpose of this study is to evaluate the PK of aleniglipron in participants with Hepatic Impairment to establish scientifically guided dosing recommendatio…

Hepatic Impairment

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT07872033

Phase 1

Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms

This phase I trial studies the side effects and best dose of pacritinib when given together with venetoclax and azacitidine in treating patients with accelerat…

Myeloproliferative Neoplasm

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Roswell Park Cancer InstituteNCT07679334

Phase 1

Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma

This phase I/II trial tests the safety, side effects, best dose and how well giving selumetinib with trastuzumab deruxtecan (DS-8201a) works for the treatment …

Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage III Pancreatic Cancer AJCC v8+2 more

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT07619521

Phase 1

Window of Opportunity Study of Lixumistat in Patients With Newly Diagnosed Glioblastoma

The purpose of this study is to determine the effect of Lixumistat in patients with newly diagnosed Glioblastoma.

Glioblastoma

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Macarena De La Fuente, MDNCT07884344

Observational

Improving Goals of Care Conversations With Hematopoietic Cell Transplant Survivors (IMPACT - HCT)

This clinical trial evaluates the impact of patient navigation and the Planning Advance Care Together (PACT) website, either alone or in combination with one a…

Hematopoietic and Lymphatic System Neoplasm

Estimated

~$10 – $750

Actual pay is set by the research site.

Fred Hutchinson Cancer CenterNCT07052630

Phase 3

Cannabidiol-Enhanced Cognitive Behavioral Therapy for Generalized Anxiety Disorder

This randomized, double-blind, placebo-controlled clinical trial investigates the use of Food and Drug Administration (FDA)-approved cannabidiol (EPIDIOLEX®) a…

Generalized Anxiety Disorder (GAD)Anxiety Disorders

Estimated

~$50 – $1,500

Actual pay is set by the research site.

Wayne State UniversityNCT07123467

Phase 3

Randomized, Prospective, Double Blind, Multi-Center, Phase 3 Pivotal Clinical Trial to Compare Efficacy and Safety of CARTISTEM® and Surgical Comparator in Subjects With Knee Cartilage Lesions and Osteoarthritis

To establish the efficacy and safety of CARTISTEM®, a combination product composed of allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUC…

Knee Cartilage Defects

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Medipost, Inc.NCT07339111

Phase 1

Phase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Background: Myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) are blood disorders that can cause serious complications …

Myelodysplastic Syndromes

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT06303193

Phase 1

Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoieti…

Sickle Cell Disease

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Mark Walters, MDNCT04774536

A Registry of Cases of Spinal Muscular Atrophy Diagnosed in the Prenatal Period That Received Disease-Modifying Therapy

Because no long-term record of prenatal Spinal Muscular Atrophy (SMA) treatment exists, this study will address an important gap in the understanding of the sa…

Spinal Muscular Atrophy

Estimated

~$10 – $750

Actual pay is set by the research site.

St. Jude Children's Research HospitalNCT07805278

Phase 1

Research Investigating Drug Effects-2 (RiDE-2)

The purpose of this study is to better understand how people's mood, behavior, and brains respond to different recreational drugs. We are also trying to unders…

Cannabis UseSubstance Use Disorder (SUD)Healthy

Estimated

~$500 – $7,500

Actual pay is set by the research site.

University of Illinois at ChicagoNCT06758596